The global rare cell isolation market size is anticipated to reach USD 3.46 billion by 2030, registering a CAGR of 9.71% from 2024 to 2030, according to a new report. This is attributed to the continuous technological advancements, increasing prevalence of chronic diseases, growing demand for personalized medicine, and advancements in cancer research. Furthermore, the isolation of rare stem cells is essential for regenerative medicine and stem cell therapy, thereby propelling the demand over the forecast period.
The COVID-19 pandemic has positively impacted the market by accelerating diagnostics and therapeutic research advancements. The urgent need to understand the virus and develop effective treatments has stimulated investment in cutting-edge cell isolation technologies, facilitating the rapid isolation and analysis of rare immune cells and circulating viral particles. Thus, the growing demand has driven innovation and collaboration across the biotech industry, resulting in enhanced single-cell analysis, liquid biopsy, and personalized medicine capabilities, boosting the demand for rare cell isolation over the forecast period.
The increasing prevalence of chronic diseases, especially cancer, has significantly increased the demand for rare cell isolation techniques. Isolation of these cells allows for early diagnosis, monitoring of treatment efficacy, and development of targeted therapies tailored to individual patients. By capturing and studying these rare cells, researchers and clinicians are anticipated to identify specific genetic mutations, recognize tumor behavior, and devise personalized treatment plans, ultimately improving patient outcomes and advancing the field of oncology. Thus, the growing demand for rare cells in predicting behavior is estimated to propel the market growth over the forecast period.
However, advanced rare cell isolation technologies, such as microfluidics and flow cytometry, often require significant investment. The high equipment, reagents, and maintenance costs can be prohibitive for many research institutions and clinical labs, limiting market expansion. In addition, the processes involved in rare cell isolation are technically complex, thus requiring specialized expertise and training. This complexity is anticipated to create a barrier to adoption, further hampering the market's growth.
This product will be delivered within 2 business days.
The COVID-19 pandemic has positively impacted the market by accelerating diagnostics and therapeutic research advancements. The urgent need to understand the virus and develop effective treatments has stimulated investment in cutting-edge cell isolation technologies, facilitating the rapid isolation and analysis of rare immune cells and circulating viral particles. Thus, the growing demand has driven innovation and collaboration across the biotech industry, resulting in enhanced single-cell analysis, liquid biopsy, and personalized medicine capabilities, boosting the demand for rare cell isolation over the forecast period.
The increasing prevalence of chronic diseases, especially cancer, has significantly increased the demand for rare cell isolation techniques. Isolation of these cells allows for early diagnosis, monitoring of treatment efficacy, and development of targeted therapies tailored to individual patients. By capturing and studying these rare cells, researchers and clinicians are anticipated to identify specific genetic mutations, recognize tumor behavior, and devise personalized treatment plans, ultimately improving patient outcomes and advancing the field of oncology. Thus, the growing demand for rare cells in predicting behavior is estimated to propel the market growth over the forecast period.
However, advanced rare cell isolation technologies, such as microfluidics and flow cytometry, often require significant investment. The high equipment, reagents, and maintenance costs can be prohibitive for many research institutions and clinical labs, limiting market expansion. In addition, the processes involved in rare cell isolation are technically complex, thus requiring specialized expertise and training. This complexity is anticipated to create a barrier to adoption, further hampering the market's growth.
Rare Cell Isolation Market Report Highlights
- The reagent & kits segment dominated the market in 2023 and is expected to grow at the fastest CAGR from 2024 to 2030. The cost-effectiveness of reagents and kits compared to more sophisticated and expensive equipment for cell isolation plays a significant role in their widespread adoption
- The stem cell type segment held the largest share of 39.46% in 2023. The pharmaceutical and biotechnology industries rely heavily on isolated stem cells to screen for new drugs, study cellular responses, and assess the safety of potential treatments. This widespread application in research and industry underpins the segment dominance
- The microfluidics-based techniques technology segment dominated the market in 2023. Continuous innovation & advancements in microfluidics technology contributed to its leading position in the market. Researchers and companies are developing new microfluidic devices and methods that offer improved performance, ease of use, and integration with other analytical tools. These advancements are driving widespread adoption and expanding the applications of microfluidics-based cell isolation
- North America dominated the market in 2023 due to the growing cancer incidence, sedentary lifestyle, and rising prevalence of chronic diseases. On the other hand, Asia Pacific is anticipated to grow at the highest CAGR over the forecast period
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Rare cell isolation market Variables, Trends & Scope
Chapter 4. Rare Cell Isolation Market: Product Estimates & Trend Analysis
Chapter 5. Rare Cell Isolation Market: Cell Type Estimates & Trend Analysis
Chapter 6. Rare cell isolation market: Technology Estimates & Trend Analysis
Chapter 7. Rare cell isolation market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Miltenyi Biotec
- Thermo Fisher Scientific, Inc.
- Danaher
- QIAGEN N.V.
- Bio-techne
- STEMCELL Technologies
- CELLENION
- RareCyte
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | July 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 1.83 Billion |
| Forecasted Market Value ( USD | $ 3.46 Billion |
| Compound Annual Growth Rate | 9.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
